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ABSTRACT 
The United States Pharmacopeia I National Formulary (USP/NF) sets the 
standards and maintains monographs for the evaluation of various dosage forms, 
especially during the storage and distribution channels. This document is compiled with 
the critical review of the stability testing of pharmaceutical products. In particular, it 
considers the progress toward globalization and harmonization, attention being directed 
to monitoring stability in the distribution channels. It is also focussed on the implications 
of Mean Kinetic Tempearature (MKT) concept and the effect of temperature spikes on 
MKT values, thus effecting the stability of drug products. The assignment of 
conformance period to the tablets were determined using the NIR stability indicating 
assay, both with the original data and the normalized. The stability of compounded 
cefazolin ophthalmic solution was studied for the various Arrhenius parameters and 
Beyond-use date assignment. 
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PREFACE 
This document was prepared in the format of the manuscript plan in accordance to 
section 11-3 of the Graduate Manual at the University of Rhode Island. This thesis is 
divided into three sections. 
Section I contains a general introduction to the objectives of my research. Section 
II consists of the main body of this thesis and is composed of four manuscripts written in 
the format required for each scientific journal they have been or will be submitted to. 
Section III contains Appendices A, B & C, which include the list of manuscripts for 
publication, role of co-authors in papers, and additional information and experimental 
details useful for the clear understanding of the work in Manuscript III respectively. A 
summary of overall conclusions and bibliography for the entire thesis follows this 
section. 
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INTRODUCTION 
It has been known for many years that many drug products have the potential to 
degrade on storage. In some instances, instability problems are so acute as to result in the 
product becoming unfit for use (i .e. lacking in acceptable safety, efficacy or patient 
acceptability) in a quite short time - in extreme instances in only a few days (1). 
In the United States, USP (The United States Pharmacopoeia) and FDA (Federal 
Food and Drug Administration) have, during the past thirty years, developed well-proven 
methods that ensure drug product stability when pharmaceuticals are maintained under 
the conditions of storage indicated on the label. 
However, there is a good reason to believe that products in the channel of 
distribution between the manufacturer and the user are not always stored in full 
compliance with label instructions (2). It seems possibly that the growth of community 
pharmacist compounding and mail order pharmacy practice may further complicate drug 
stability. Thus, the stability of drug products in the channel of distribution is in urgent 
need of definition. It is known that both USP and FDA are concerned about this problem. 
The advancement of technology and the availability of high performance liquid 
chromatography (HPLC) have been a boom in the field of pharmaceutical stability 
testing. In addition to the technology advancement, organizational and regulatory 
developments have also been of great significance in stability testing. 
The acceptance of USP definition of Controlled Room Temperature (CRT) and 
Mean Kinetic Temperature (MKT) concept has gained the attention of regulators in both 
the European Union and the United States (3,4). In this particular document, some of the 
implications of MKT on the drug product stability and the effect of temperature 
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excursions on the shelf life of drug products were investigated. The assignment of 
conformance period to the tablets using the NIR stability-indicating assay is also given a 
berth. Also reported some preliminary studies of the chemical stability of compounded 
cefazolin sodium ophthalmic solution. 
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OBJECTIVES 
The objectives of this thesis are mentioned as four points, all of which are related to one 
another, basically relating to the drug stability and are as follows. 
1) To study the theoretical aspects related to drug stability, the problems encountered 
during distribution and storage, the ways to calculate MKT, the concepts of 
compounding and beyond-use date. Attention is also to be given for the 
globalization and harmonization of stability testing of drug products. 
2) To study some of the implications of the MKT concept and the effect of 
temperature excursions I temperature spikes on the drug product stability. 
3) To investigate the Arrhenius parameters and assign the Beyond-use dates for the 
compounded Cefazolin ophthalmic solution. 
4) To estimate the shelf life of the tablets using the NIR stability indicating assay. 
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Trends in Stability testing with emphasis on stability during distribution and 
storage 
*Published in Drug Development and Industrial Pharmacy, 25(7): 857-868 (1999) 
Abstract 
This paper reviews contemporary trends in the stability testing of pharmaceutical 
products. In particular, it considers the progress toward globalization and harmonization 
and indicates stability problems, which probably will be the focus of attention for 
pharmaceutical scientists and regulators in the near future. Attention is specifically 
directed to monitoring stability in the channels of distribution. 
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INTRODUCTION 
Within the past twenty-five years or so, the stability testing of pharmaceutical 
products has advanced dramatically from a somewhat haphazard exercise which showed 
dramatic variations in quality, both within and between various jurisdictions, to an 
operation based on sound scientific principles, which shows a significant degree of 
commonality in many parts of the world. 
Although pharmaceutical scientists and regulators have known for many years 
that all drug delivery systems - to a varying degree - have a propensity to degrade and 
thus show a lower level of "fitness for use", it was only in the nineteen seventies that 
standardized approaches for the reliable quantification of the stability of pharmaceutical 
products began to emerge. 
The stability of pharmaceutical products is a broad area encompassing many 
potential routes of degradation. Any change which occurs in a pharmaceutical product, 
subsequent to its preparation, that adversely affects any attribute of the quality of the 
product in terms of its fitness for use by a patient is, potentially at least, a matter of 
concern to pharmaceutical scientists and regulators involved in stability testing. 
It is conventional and convenient to classify degradation of pharmaceutical 
products as being chemical, physical or biological. However, in many instances these 
distinctions are not complete. For example, oxidation in a condom (chemical) results in a 
loss of tensile strength (physical). Also, for many drugs or devices more than one mode 
of degradation may be possible. (1) 
In general, we may classify the adverse effects of pharmaceutical product ' s 
instability as modifying efficacy, safety, or ease of use or patient acceptability. In terms 
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of efficacy the most obvious effect is loss of potency of the drug. Indeed, for many 
stability studies loss of potency is the key factor in the determination of the shelf life of 
the product. Usually we regard 90% of label claim as being the lowest acceptable value 
of potency. Thus, for many pharmaceutical products an estimation of the time, which will 
elapse (when the product is stored under specified conditions) before the potency, is less 
than 90% of label claim will be central to our stability studies. 
Important, though loss of potency can be there, is now an increasing recognition 
that for some pharmaceutical products other effects of instability may be of equal or of 
greater importance than loss of potency. For example, if a degradation product is toxic it 
may be that the accumulation of the toxic degradation product is of more critical 
importance than loss of active. Although such occurrences are presently probably 
relatively rare, the increasing use of protein drugs, for which small changes in structure 
can have profound impact on immunogenicity, may result in this situation becoming 
more likely and therefore deserving of more attention. 
In considering the stability of pharmaceutical products it is essential to consider 
the totality of the product: drug, excipients, pack and label. All of these elements can play 
an important role in the fitness for use of the drug delivery system. For example, if 
migration of a plasticizer from the plastic bottle into a label causes the ink to become 
blurred so that the legibility of the information on the label is impaired, this is a matter of 
concern. 
A major factor in the improvement of pharmaceutical stability testing has been the 
development of analytical methods, which are suitable for use in stability indicating 
assay. In particular, the availability of high performance liquid chromatography (HPLC) 
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has been a real boon to stability testing. It is noteworthy that our definition of a stability-
indicating assay has evolved from a method that would allow quantification of a drug in 
the presence of its degradation products and excipients to a method, which allow 
quantification not only of the drug but also major degradation products. 
In addition to technical achievements, such as the emergence of HPLC for use in 
stability indicating assays, organizational and regulatory developments have also been of 
great significance in stability testing. During recent years the substantial number of 
corporate takeovers and mergers has increased the number of pharmaceutical companies, 
which operate in many areas of the world. For such transnational corporations there is an 
obvious attraction to using the same raw materials, equipment, production methods and 
quality control tests at all their plants throughout the world. Thus such companies have an 
especially strong interest in promoting compatibility in regulatory policies such as those 
which control stability testing. 
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STABILITY 
Concepts 
Stability testing is a routine procedure performed on drug substances and 
products. It is involved at various stages of a product's development. In early stages, 
accelerated stability testing (at relatively high temperatures and I or humidities) can be 
used for some drugs as a "worst case" evaluation to determine what types of degradation 
products may be found after long-term storage. Testing under less rigorous conditions 
(those recommended for long- term shelf storage), and slightly elevated temperatures, can 
be used to determine a product's shelf life and expiration dates (2). Stability testing is 
performed to ensure that drug products retain their fitness for use up to the end of their 
expiration dates. (3) 
The raison d'etre of pharmaceutical testing should be to provide reasonable 
assurance that the "fitness for use" of our products remains at an acceptable level 
throughout the period during which they are in the market place available for supply to 
the patient/consumer. It has been suggested by some that the above definition should be 
extended so that it covers the period until the patient uses the last unit of product. 
However, since we cannot control how patients store drugs and because we are aware 
that a significant proportion of patients store pharmaceuticals in a quite inappropriate 
manner, many pharmaceutical scientists believe this concept to be impracticable. The 
most likely method of improving storage of drug products by patients may well be in 
individual counseling by pharmacists 
Stability of a pharmaceutical product may be defined as the capability of a 
particular formulation, in a specific container/closure system to remain within its 
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physical, chemical, microbiological, therapeutic, toxicological, protective and 
informational specifications. Although there are exceptions, 90% of labeled potency is 
generally recognized as the minimum acceptable potency level ( 4 ). Stability is also 
defined as the extent to which a product retains, within specified limits, and throughout 
its period of storage and use (i.e., its shelf life), the same properties and characteristics 
that it possessed at the time of its manufacture. The criteria for acceptable levels of 
stability have been reviewed in the form of a table. (5 ,6) 
Factors affecting Product Stability 
Many factors affect the stability of a pharmaceutical product, including the 
stability of the active ingredient(s), the potential interaction between active and so-called 
inactive ingredients, the manufacturing process, the dosage form, the container closure 
system, the environmental conditions encountered during shipment, storage, handling, 
and length of time between manufacture and usage. Environmental properties such as 
heat, light, and moisture as well as chemical factors like, oxidation, reduction, hydrolysis, 
or racemization, can all play vital roles in pharmaceutical stability. Degradation reactions 
in pharmaceutical formulations may depend on such conditions as concentration of 
reactants, pH, radiation, temperature and catalysts etc (7). A number of other factors are 
listed in the literature. Of all the many environmental factors, which can be involved in 
drug degradation, temperature is the most important one, which cannot be controlled by 
package selection.( 4) 
The stability of a drug product depends on the raw materials used, warehouse and 
transport facilities, patient/consumer storage and in-vivo stability. The effects of drug 
product instability include loss of active drug (e.g., nitroglycerin tablets), increase in 
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concentration of active ingredient (e.g. , lidocaine gel), change in biological activity (e.g., 
tablet aging), loss of content uniformity (e.g. , flocculation and impaction in suspensions), 
presence of pathological microorganisms (e.g., contamination of a multi use cream), loss 
of pharmaceutical elegance (e.g. , yellowing of direct compression lactose tablets 
containing an amine drug), production of toxic decomposition products (e.g., conversion 
of tetracycline to epianhydrotetracycline) and other factors changing fitness for use (e.g., 
adhesion aging of transdermals). (8) 
Expiration Date I Shelf life 
An Expiration date is defined as the time up to which the preparation will remain 
stable when stored under recommended conditions. Thus, an exp iration date is the date 
beyond which it is predicted that the product may no longer retain fitness for use. If the 
product is not stored in accordance with the manufacturer's instructions, then the product 
may be expected to degrade more rapidly. Strict adherence to the storage requirements 
specified in the product labeling will help ensure product stability through to the 
manufacturer ' s labeled expiration date. The manufacturer ' s expiration date only applies if 
these storage requirements are met from the time the product leaves the manufacturer 
until it is supplied to the user. (9) 
Shelf life is the time during which we have reason to believe that the product, if 
stored appropriately, will retain fitness for use (>90% oflabel claim of potency) (10). The 
expiration date is also defined as the date placed on the container/labels of a drug product 
designating the time during which a batch of the product is expected to remain within the 
approved shelf-life specification if stored under defined conditions, and after which it 
may not be used (11). The use of kinetic and predictive studies for establishing credible 
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expiration dates for pharmaceutical products are now accepted worldwide. However, 
prior to about 1950 only qualitative or semi-quantitative methods and procedures were 
commonly used in pharmaceutical studies. Stability study requirements and protocol 
designs were covered in detail in the standard professional literature. (10-13) 
Although shelf life may be in some instances be estimated by accelerated stability 
testing protocols, real time product stability testing is necessary to validate stability 
claims (14). Additional data pertinent to shelflife may be obtained using the retained 
samples, from market challenge tests and test distributed samples, and from returned 
samples. (8) 
15 
ST ABILITY TESTING METHODS 
Real -Time Stability Testing 
In real-time testing, the duration of the test period should normally be long 
enough to allow significant product degradation under recommended storage conditions. 
Alternatively, if a product is essentially stable the test should be conducted for a long 
enough period to clearly indicate that no measurable degradation is occurring. At the 
least, the testing protocol must permit one to distinguish degradation from inter assay 
variation. For example, data may be collected at an appropriate frequency such that a 
trend analysis may discern instability form day-to-day imprecision. The reliability of data 
interpretation can be increased by including in each assay a single lot of reference 
material with established stability characteristics. Sample recovery between assays can be 
thereby normalized to this reference, minimizing the impact of systematic drift and inter 
assay imprecision. Frequently, however, an appropriate reference material is not available 
for use as a control. When one measures the stability of a reference material, imprecision 
may be introduced by changes in both reagents and instrumentation. Ideally, reagents 
should be sufficiently stable that a single lot provides unchanging performance 
throughout the stability study and instrument performance should remain constant. 
However, one must monitor system performance and control for drift and discontinuity 
resulting from changes in both reagents and instrumentation. (14) 
The time at which the 90% two sided lower confidence bound intersects at 90% 
potency level on the stability plot (percent of label claim against time) is best termed the 
Conformance period. This length of time must always be greater than the actual shelf life 
that is assigned to the product. The Conformance period may, of course, be any time 
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interval e.g. , 21.3 months, 38.7 months or 69.5 months. The shelflife is rounded down 
from the Conformance period to give a convenient value e.g., 18 months, 3 years or 5 
years. Full details of the method of calculation are given in the FDA Guidelines (12) . 
Accelerated Stability Testing 
Accelerated stability testing refers to methods by which product stability may be 
estimated by storage of the product under conditions that accelerate degradation 
commonly by an increase in temperature. Stress conditions that accelerate change fall 
under the general headings of temperature, light, moisture, agitation, gravity, pH, 
packaging, and method of manufacture. This method is often used to provide an early 
indication of product shelf life and thereby shorten the development schedule. This may 
permit in some circumstances the prediction of the stability of the product at ordinary 
shelf temperature from data obtained by stress testing. A reasonable statistical treatment 
in accelerated stability projections based on the Arrhenius equation normally requires that 
at least four stress temperatures be used. Many accelerated stability-testing models are 
based on the Arrhenius equation. ( 15-18) 
k = A e -Ea/RT 
where k is a rate constant at temperature T (in degree Kelvin), Ea is the activation energy, 
and R is the gas constant. This equation describes the relationship between storage 
temperature and degradation rate. Use of the Arrhenius equation permits a projection of 
stability from the degradation rates observed at high temperatures for some degradation 
processes. (19) When the activation energy is known, the degradation rate at low 
temperatures may be projected from those observed at "stress" temperatures. 
17 
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Bracket Tables 
The bracket table technique assumes that, for a given analyte, the activation 
energy is between two limits, e.g., between 10 and 20 kcal. As a result, a table may be 
constructed showing "days of stress" at various stress temperatures. Readers are 
requested to view the table from ( 14 ). The use of a 10 to 20 kcal bracket table is 
reasonable, because broad experience indicates the most analytes and reagents of interest 
in pharmaceutical; and clinical laboratories have activation energies in this range. (23,24) 
For analytes with high activation energies, both bracket tables and the Q rule 
provide useful information when they are applied conservatively. Use of published or 
experimentally derived activation energy values can significantly lower the risks inherent 
in projecting product shelf life. 
The Q rule and the Bracket tables were used in the past by some in the 
pharmaceutical for the prediction of shelf life of the product. These methods are not 
official either in the ICH or FDA Stability Guidelines. 
Retained Sample Stability Testing 
One of the most important elements in most stability testing of marketed 
pharmaceutical product is evaluation of retained stability samples. The usual practice for 
such studies is that for every marketed product, for which stability data is required, the 
manufacturer selects stability samples form retained storage for at least one batch a year. 
If the number of batches marketed exceeds 50 it is probably desirable to take stability 
samples from two batches. Often when a new product is first introduced on to the market 
the manufacturer may decide to take stability samples of every batch. Later as increased 
confidence is gained in the stability of the product the number of batches kept on stability 
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testing is likely to be progressively reduced so that only two to five percent of marketed 
batches are designated as stability sample batches. (8) 
Stability samples are tested at predetermined intervals. Thus, if a product has a 
five-year shelf life, it is conventional to test at 3,6,9,12,18,24,36,48,and 60 months. This 
conventional method of obtaining stability data on retained storage samples was termed 
as "Constant Interval Method" by Carstensen and Rhodes (8) who pointed out some 
disadvantages of this method earlier. (25,26). These authors have proposed use of the 
first, the Fixed Date method of stability sample testing, which uses a modified form the 
conventional retained sample testing. They also proposed a much more radical change 
and termed this method as "Stability Testing by Evaluation of Market Samples". This 
method involves taking samples already in the marketplace and evaluating stability 
attributes (27-29). This type of testing is inherently more realistic since it challenges the 
product not just in the idealized retained sample storage conditions, but also in the actual 
market place. 
6. Cyclic-Temperature Stress Testing 
This method, as explained by Carstensen and Rhodes, (30) may provide evidence 
about the instability not available from isothermal tests. This type of testing is a very 
useful component in the gamut of tests available to the pharmaceutical scientist for 
stability testing (1,29), used in development or trouble shooting but not for routine testing 
of marketed product. The cyclic temperature stress tests should be designed based on 
knowledge of the product, so as to mimic likely conditions in market place storage. The 
period of the cycle mostly favored is as 24 hours since the diurnal rhythm on earth is 24 
20 
hours and thus marketed pharmaceuticals are most likely to experience such a cycle 
during storage. (31 ,32) 
Carstensen and Rhodes (32) derived an equation relating temperature change to 
time based on a sine wave, function. It was proposed that the maximum and minimum 
temperatures for the cyclic stress testing should be selected on product by product basis 
and taking into account such factors as recommended storage temperatures for the 
product and specific chemical and physical degradation properties. It was also 
recommended that the test should normally have about twenty cycles. 
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MEAN KINETIC TEMPERATURE (MKT) 
Concepts 
For an USP/NF product it is expected that, when properly stored, the product can 
meet monograph specifications at any time during its shelf life. From time to time, health 
care practitioners have expressed concerns about the environmental stresses to which 
drug products are exposed throughout the product's lifetime and about whether the 
exposure will effect the articles' integrity. The concerns include transportation and 
storage of drug products by manufacturers, wholesalers, and pharmacies. Thus, the 
stability of the pharmaceutical article is an attribute that must be known. The USP/NF 
recognized that storage temperature affects stability and thus defined the storage 
conditions. 
The amendment of the USP definition of Controlled Room Temperature in 
November 1993 includes a requirement for "a mean kinetic temperature calculated at not 
more than 25 °C''. The definition of Controlled room temperature is as follows: 
"A temperature maintained thermostatically that encompasses the usual and 
customary working environment of 20 °c to 25 °c that results in a mean kinetic 
temperature calculated to be not more than 25 °c; and that allows for excursions between 
15 °c and 30 °c that are experienced in pharmacies, hospitals, and warehouses. Articles 
may be labeled for storage at "controlled room temperature" or at" up to 25 °C", or other 
wording based on the same mean kinetic temperature". (33,34) 
The relationship between CRT ant MKT for storage and distribution of 
pharmaceutical articles is given special attention in official publications. (11,35) 
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Since degradation rate constants are temperature-dependent, the amount of degradation 
varies with the temperature during a storage period. The use of Mean Kinetic temperature 
(MKT) originally proposed by Grimm (36) has become generally accepted as a 
convenient method of quantifying storage temperatures as they relate to degradation. 
The equation for the determination of MKT is derived from Arrhenius equation, 
relating the degradation rate constants at different temperatures to the activation energy 
and is known as Haynes formula (37). The MKT concept can be applied to many areas of 
pharmaceutical distribution, namely, to manufacturers, warehouses, shippers, hospitals 
and community pharmacies, emergency vehicles, sales representatives' vehicles, etc. 
Mean Kinetic Temperature is the single calculated temperature at which the total 
amount of degradation over a particular period is equal to the sum of the individual 
degradations that would occur at various temperatures. Thus, the mean kinetic 
temperature may be considered as an isothermal storage temperature that simulates the 
nonisothermal effects of storage temperature variation (38,39). It is not a simple 
arithmetic mean. It is always higher than the arithmetic mean temperature. (39) 
Calculation of MKT 
Although there is general recognition in North America, the European Union and 
Japan of the utility of the MKT concept, there is still some debate about the exact method 
by which this value should be calculated, although in many instances the differences in 
mode of calculation will have little significant effect on numerical value obtained. 
USP Method 
The USP method of calculation ( 40) is shown below. The mean kinetic 
temperature is calculated from the average storage temperatures recorded over a one year 
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period and running average calculated from the average of weekly high and low 
temperatures recorded over the preceding 52 weeks. If the exposure of the 
pharmaceuticals is for a lesser period (as in doctor' s cars, patient' s cars, sales 
representatives' cars etc.), then it is advised to calculate the MKT with frequent recording 
of the temperature profile. 
The mean kinetic temperature is calculated by the Haynes ' equation: 
~HIR 
MKT 
-In ((e-t.H/RTI + -t.H/RT2 + + -t.1-1/RTn) I ) e .... . .. . e n 
Where MKT is the mean kinetic temperature; ~ is the heat of activation, 83 .144 
kl/mole; R is the universal gas constant 0.0083144 kl/mole/degree; T 1 is the arithmetic 
mean of the highest and lowest temperatures recorded during the first time period, e.g. , 
the first week; T 2 is the arithmetic mean of the highest and lowest temperatures recorded 
during the second time period, e.g., second week; Tn is the arithmetic mean of the highest 
and lowest temperatures recorded during the nth time period, e.g., nth week, n being the 
total number of average storage temperatures recorded (52) during the annual observation 
period; and all temperatures, (T) being absolute temperatures in degrees Kelvin (K). 
In reality, of course, not all pharmaceutical products are characterized by 
degradation energy of activation as 83kJ/mole. This is the average value based on work 
by Grimm (36) and Kennon (24). Ideally, the value of activation energy, ~H, to be used 
in the calculation should be determined experimentally for any given product. Among 
various pharmaceutical dosage forms, the activation energy may vary from 5-240 
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kJ/mole. The change in MKT that results from this variation of activation energies is 
probably relatively small in many instances (39). 
FDA method 
FDA recommends the method of entering both the individual highest and the 
lowest temperatures (rather than averages) in the equation for the calculation of MKT. 
This results in entering 104 data points in contrast to USP 's 52 points (13). Bailey and 
Medwick ( 40) have discussed the characteristics of methods used to calculate MKT. 
The USP and the FDA methods of calculation of MKT were compared by the 
authors, taking into consideration, the different values for the activation energy. (41) 
If temperatures are electronically recorded at many times during a day and all the 
values used in the calculation of MKT then there is no difference between the USP and 
FDA methods. 
Mail Order Temperature Excursions 
Factors that may affect the stability of a drug product during shipment include the 
specific nature of the product, the types of packaging, and variations in environmental 
conditions during transport. Since many pharmaceutical products are distributed through 
United States postal service, a study was performed by Black and Layloff ( 42) which 
revealed the interior temperature of a black mail-box was 58 °c in an ambient 
temperature of 38 °c at St.Louis, Missouri. This result indicates that pharmaceutical 
products distributed through the postal service may be exposed to temperatures that 
significantly exceed those normally specified in stability standards. This is especially 
likely to be a problem for temperature sensitive (labile) products. 
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In order to observe the effects experienced by the packaged pharmaceuticals 
during the shipment and distribution, the USP recorded the temperatures and humidities 
experienced by packages during mail-order distribution by packaging temperature and 
humidity monitoring devices and shipping to different parts of the country. On return of 
the packages, the MKT was calculated. Results of the study have shown that only 8.4% 
of the packages experienced temperature variations within the excursions allowable under 
the CRT. The remaining packages were exposed to temperatures significantly above the 
accepted excursion range. While 65.5% of the packages experienced warm conditions 
(30°C - 40 °C) during the shipment, the remaining 26.1 % experienced excessive heat 
(>40 °C) conditions. Additionally, MKT calculations have shown that 31.1 % of the 
packages had MKT values above 25 °c for periods of 19 to 21 days. Significant spikes in 
relative humidity experienced were also reported. ( 43) 
The USP team of scientists also studied to determine the extent of physical and 
chemical changes experienced by the pharmaceutical preparations exposed to typical 
shipping conditions. Monitoring devices were used for the study. Results of temperature 
and humidity variations during shipment indicated about 40% of the articles experiencing 
MKT greater than 25 °c (44). The data presented agreed with previous findings, 
demonstrating that the pharmaceuticals experience significant fluctuations in temperature 
and humidity during shipment. 
Recognizing that some products will especially be sensitive to temperature 
change, USP proposed a definition of "Labile" preparations and the shipping and the 
labeling requirements for such preparations ( 45). 
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The data profile of the temperatures experienced during the shipment and 
distribution can be obtained using electronic indicators as TempTale 3, TempTale H, and 
Cox Lynx and chemical indicators as Time temperature indicator (TTI) and Monitor 
Mark. The functioning of the indicators were dealt by C.C.Okeke et.al (43). It has also 
been reported by Carstensen that MKT in Sudan is in excess of that stipulated for the 
"dry, hot" climate zone. (46) 
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STORAGE CONDITIONS 
Concepts 
USP compendia! monographs specify storage requirements that are to be 
maintained throughout the shelf life, shipment, distribution, and storage of the article. 
USP storage requirements fall into two major categories, specific and non-specific 
(33,47). Many monographs include specific storage conditions, such as "Store in a cool 
place". A survey conducted by the USP revealed that there exist products, which do not 
have any specific storage conditions ( 48). The USP General Notices section addresses 
these types of compendia! monographs in Storage under non-specific conditions. 
The storage conditions under the specific requirements are defined using the 
terms: freezer, cold, cool, Room temperature, Controlled room temperature, warm, 
excessive heat, and protection from freezing. The storage under non-specific conditions 
states that for articles, regardless of quantity, where no specific storage directions or 
limitations are provided in the individual monograph, it is to be understood that 
conditions of storage and distribution (including the shipment of articles to the consumer) 
include protection from moisture, storage at controlled room temperature, and, where 
necessary, protection from light. (3 3) 
The length of the stability studies and the storage conditions should be sufficient 
to cover storage, shipment, and subsequent use (e.g., reconstitution or dilution as 
recommended in the labeling). The accelerated and long-term storage conditions and the 
minimum time period at submission are listed below. 
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Conditions Minimum time period at Submission 
Long-term testing 25 °c +/- 2 °c I 60 +/- 5% RH 12 months 
Accelerated testing 40 °c +/- 2 °c I 75 +/- 5%RH 6 months 
Where "significant change" occurs due to accelerated testing, additional testing at 
an intermediate condition, e.g., 30 °c +/-2 °c I 60+/- 5% RH may be used (49). The data 
(from accelerated testing or from testing at an intermediate condition) may be used to 
evaluate the impact of short-term excursions outside the label storage conditions such as 
might occur during shipping. 
Testing under the defined long-term conditions will normally be every three 
months during the fust year, every six months during the second year, and then annually. 
The long-term testing should be continued for a sufficient period beyond 12 months to 
cover shelf life at appropriate test periods. The further accumulated data should then be 
submitted to the authorities during the assessment period of the Registration application. 
The containers to be used in the long-term, real time stability evaluation should be the 
same or as simulate the actual packaging used for storage and distribution. 
Heat sensitive products should be stored under an alternative lower temperature 
condition, which will eventually become the designated long-term storage temperature. 
Where a lower temperature storage condition is used, the six months accelerated testing 
should be carried out at 15 °c above its designated long-term storage temperature. For 
example, if a product is to be stored long term under refrigerated conditions, accelerated 
testing should be conducted at 25 °c +/- 2 °C/60% +/- 5% RH. The designated long-term 
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testing conditions will be reflected in the labeling and expiration date. A storage 
temperature range indicated on the label may be used in accordance with relevant 
national/regional requirements. 
For products where water loss may be important, such as liquids or semi-solids in 
plastic containers, it may be more appropriate to replace the high RH conditions by lower 
RH, such as 10-20%. (11) 
Temperature and hwnidity determines the climatic and storage conditions. Both 
factors greatly affect the stability of a drug product. Since the temperature and humidity 
however constantly change - day and night alteration, seasonal variations-, 
considerations regarding the sorption behavior of the drug and the permeability of 
packaging materials must also be included (50). There are a several of studies reporting 
the changes in characteristics of tablets (51-57) and other dosage forms upon storage. 
Climatic zones 
For convenience in assigning shelf life stability experts have divided the world 
into four climatic zones (Table D (58) based on their MK.Ts and relative humidities. The 
zones are characterized as follow with the corresponding storage conditions (59). The 
criteria and guide values for assignment of a city to the correct climatic zones are listed in 
Table II. (60,61) 
The basis of the derived storage conditions were climatic values, measured in the 
open. They covered an average time span of 20 years and are therefore taken as 
representative for each place. These climatic values were then corrected, because drugs 
are not stored in the open. The average values for temperature and partial pressure of 
water vapor so obtained were provided with a safety factor. (61) 
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Storage conditions for Zones I and II 
About 85% of the trade in pharmaceutical products in the world is undertaken 
within the areas of the EU, Japan and the USA. Therefore, it was obviously useful to 
have one storage condition, which could cover all these territories. 
Uniform storage conditions are a basic requirement. In the EU most of the 
population live in climatic zone I or II, in Japan 99% and in the USA 94%. Since climatic 
zone II is a worst case situation for the EU and most of Japan and the US a MKT of25 °c 
covers all those areas. The measured conditions in many warehouses are well below the 
storage conditions for climatic zone II, giving an indication of the safety margin. 
All areas in climatic zones I and II in the three areas can be covered by one storage 
condition (thereby naturally including zone I as well) 25 °c /60%RH. 
Thus, it can be concluded that stability testing in the EU, Japan and the USA 
(zones I & II) can normally be performed applying the same storage conditions, 25 °c I 
60%RH for long term testing and 40 °c I 75%RH for high temperatures contain a safety 
margin, meaning that the derived shelflives also have a built-in safety margin. (3) 
Storage conditions for zones ID and IV 
If a drug substance is to be marketed in climatic zone Ill, then samples are stored 
at 30 °c I 35%RH; if the product is used in climatic zone IV, samples are stored at 30 °c I 
70%RH. (62) 
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( COMPOUNDING 
Definition 
Compounding is the process by which a pharmacist combines, mixes or alters 
ingredients to produce a medication for a patient, acting in accordance, or in reasonable 
anticipation of, a prescription issued by a physician, nurse practitioner, dentist or some 
other duly authorized person. Compounding can be as simple as adding a liquid to a 
manufactured drug powder, which has been formulated to produce a solution or a 
suspension, and as complex as the extemporaneous creation of a novel preparation. 
During the past decade there has been a significant increase in the number of 
pharmacists in the United States devoting a substantial part of their activities to 
compounding prescription, in some instances for a wide variety of drugs and drug 
delivery systems (63) . 
FDA Modernization Act of 1997 
The FDA Modernization Act of 1997 (64), added a new section (503A) on 
Pharmacy Compounding to the Federal, Food, Drug and Cosmetic Act (FDC Act). This 
act also requires FDA to establish an Expert Advisory Committee on compounding which 
will assist FDA in preparing a list of non USP drugs which may be used in compounding. 
The legislation helps to delineate legal aspects of compounding. Specifically, the 
new section 503A: (1) recognizes the triad relationship (viz. patient, physician, 
pharmacist} as the basis for the practice of compounding; (2) allows for anticipatory 
compounding; (3) sets criteria for the drug substances to be used in compounding; (4) 
describes the development of a memorandum of understanding between states and FDA 
to address interstate distribution of compounded drugs; and (5) limits advertising and 
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promotion of compounding services. Section 503A, subsection (b) of FDA 
Modernization Act of 1997 specifies the compounding of drugs by the licensed 
pharmacist and licensed physicians. 
The FDA has limited authority, to regulate pharmacists legitimately engaged in 
compounding. ( 65) 
Stability of compounded products 
With the increase in recent years in compounded prescriptions, the question most 
frequently asked is "What is the stability ofthis product after it is prepared?" In 
repackaging, diluting or mixing a product, the pharmacist should have concern about 
stability. Assurance of sterility of compounded injections or opthalmics is obviously of 
great importance. The pharmacist is responsible for the HSDs (Sterile Drug Products for 
Home Use) dispensed which are of commercially available type or compounded product 
right from dispensing to the patient till the stage of consumer' s use passing through the 
phases of distribution and storage (66). 
As a final step in meeting responsibility for the stability of drugs compounded or 
dispensed, the pharmacist is obligated to inform the patient regarding the proper storage 
conditions (for example, in a cool dry place---- not in the bath room), for both 
prescription and non-prescription products, and to provide a reasonable estimate of the 
time after which the medication should be discarded. When expiration dates are applied, 
the pharmacist should emphasize to the patient that the dates are applicable only when 
proper storage conditions are used. Patients should be encouraged to clean out their drug 
storage cabinets periodically. (5) 
33 
Compounded products pose a new set of concerns, because the pharmacist does 
not always have extensive stability data. Trissel has proposed some stability monographs 
of a number of compounded drug products (67). The stability of compounded products is 
defined to be the same as that of manufactured products, officially in USP (35). 
Compounded preparations should be packaged in containers meeting USP standards. The 
information regarding the containers for packaging is dealt in detail in Sections <661 > 
and <671> of USP 23 . 
The safety, efficacy, and other quality attributes of compounded preparations 
depend on correct ingredients and calculations, accurate and precise measurements, 
appropriate formulation conditions and procedures, and prudent pharmaceutical 
judgement. The pharmacist should review each procedure in the compounding process to 
ensure accuracy and completeness, the pharmacist should be prepared to conduct such 
tests as may be necessary for any given product (68). 
Beyond-use-date 
The ICH Stability Guidelines (1993) provides uniform test conditions of 
temperature and humidity for stability testing of drug substances and products (69,70). 
With the establishment of these uniform test conditions of temperature and humidity for 
stability testing, a re-examination of beyond-use dating proposals from 1991 had taken 
place and the revised form was published in 1996. (71) 
The beyond-use date is a means of making available to pharmacists some reliable 
information for indicating to patients the date after which a prescribed medication should 
not be used. The beyond-use date applies to all the medications which are not directly 
from manufacturers such as repackaged and/or compounded and dispensed by the 
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pharmacist. Because compounded preparations are intended for administration 
immediately or following short term storage, their beyond-use dates may be assigned 
based on criteria which are not always identical to those used in assigning expiration 
dates for manufactured drug products. Beyond-use dates should be assigned 
conservative! y. 
The pharmacist is responsible to allot a justifiable beyond-use date for the 
compounded I dispensed product based on reliable information such as that available 
from pharmaceutical manufacturers or literature on the compounded product' s stability or 
from USP. All stability data must be carefully interpreted in relation to the actual 
compounded formulation. In addition to using all available stability information, the 
pharmacist will also use his or her pharmaceutical education and experience in allotting 
the beyond-use date for the compounded formulations. 
Bailey and Medwick reported the available methods of securing data on which to 
base a beyond-use date (72,73). The manufacturers may conduct the "open dish" studies 
(apart from other stability studies) to obtain the data needed to provide the pharmacist 
with the information on dispensing container selection and beyond-use date 
recommendations for solid dosage forms. The open dish study is a study in which the 
dosage forms are exposed to 60%RH at 25 °c for 30 days without any container 
protection: three samples of 30-unit doses from one lot are analyzed at 0 and 30 days. A 
detailed procedure for conducting the open-dish studies was published in PF. (74) 
In the absence of stability information that is applicable to a specific drug 
preparation, it is recommended that for non-sterile non-aqueous liquids and solid 
formulations that maximum beyond-use date not later than 25% of the time remaining 
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( until the product's expiration date or 6 months, whichever is earlier (when packed in 
tight, light resistant containers and stored at CRT unless otherwise indicated). For non-
aqueous formulations, a maximum period of 14 days is recommended as beyond-use date 
when stored at cold temperatures. 
Federal law requires that the label on the container or package of an official 
compounded preparation must bear a beyond-use date. Good pharmacy practice dictates 
beyond-use labeling for all compounded preparations. 
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CONCLUSION 
Pharmaceutical scientists and regulators may justifiably fed a sense of 
achievement when they review the progress which has been made in stability testing in 
recent decades. The increasing attention now being given to the possible effects of 
storage and transport on the stability of pharmaceutical products (manufactured or 
compounded) is well-deserved and will, hopefully, lead to a improved level of confidence 
about the quality of drug products when such items are supplied to patients. 
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Table I: World climatic zones based on their MKTs and relative humidities. 
Climatic zone Definition Storage condition 
--------------------------------------------------------------------------------------------------
Zonel N.Europe Temperate 21 °C /45%RH 
""" 
Zone2 S.Europe, Japan,US Mediterranean 25 °C /60%RH VJ 
Zone3 Sahara Hot and dry 30 °Cl35%RH 
Zone4 Central Africa,Indonesia etc. Hot and wet 30 °C/70%RH 
Table II: Criteria and guide values for assignment of a city to the correct climatic zones 
Guide values for Individual climatic zone 
Criteria I II m IV 
~ Mean annual temperature 
~ 
measured in the open air Up to 15 °c > 15-22 OC >22 OC >22 OC 
Calculated mean annual 
temperature ( <19 °c) Up to 20.5 °c >20.5-24 OC >24 OC >24 OC 
Mean annual water vapor 
partial pressure Up to 11 mbar >11-18 mbar Up to 15 mbar > 15 mbar 
MANUSCRIPT II 
45 
Effects of Temperature Spikes on Mean Kinetic Temperature and Shelf Life 
*Submitted for publication in Pharmacopeial Forum 
Abstract 
The international acceptance of the definition of Controlled Room Temperature 
(CRT) has given additional impetus to the use of Mean Kinetic Temperature (MKT) as a 
method of quantifying temperatures during transport and storage and consequent possible 
effects on drug product stability. The present paper explores some of the implications of 
the MKT concept and considers the effect of temperature spikes on MKT values and 
hence on stability of drug products. 
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( INTRODUCTION 
The USP definition of Controlled Room Temperature, CRT, is: "A temperature 
maintained thermostatically that encompasses the usual and customary working 
environment of 20 °c to 25 °c that results in a Mean Kinetic Temperature calculated to 
be not more than 25 °c, and that allows for excursions between 15 °c and 30 °c that are 
experienced in pharmacies, hospitals, and warehouses." 
MKT (1) is defined as the isothermal temperature that corresponds to the kinetic 
effects of a time-temperature distribution and determined using Haynes' formula (2) into 
which temperature data obtained at defined intervals are entered. The MKT equation is 
shown as follows: 
MKT = (i:1H/R)/ (-ln ((e-~H/RT I + e-~RT2 + ........ + e-~H/RTn) I n)) 
USP has proposed a method of calculating MKT, which enters the 52 weekly 
arithmetic means of the highest and lowest temperatures recorded over the preceding 52 
weeks for the calculation of a yearly MKT (3). The FDA recommends that, for 
manufacturers, repackagers, and warehouses, all data points obtained be inserted directly 
into the equation. A minimum of 104 weekly high and low readings recorded over the 
preceding 52 weeks would be inserted into the MKT equation to calculate a yearly MKT 
(4,5,6,7) 
In the present paper we consider some of the implications of MKT for the stability 
of drug products. In particular, we explore the effect of temperature "excursions" or 
temperature spikes on the shelf life of drug products. 
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( THEORY 
The USP definition of CRT is most useful. However, one question that has been 
raised by a number of persons, including some of the participants at the 4 June 1998 USP 
Open conference on Packaging, Storage and Distribution, is: "How long in time can the 
excursions in temperature up to 30 °c be before it is likely that there will be a serious 
adverse effect on drug product stability?" In particular: "Is it likely that for some products 
the total effect of a number of temperature excursions will be such as to invalidate a 
previously assigned expiration date or beyond-use date?" Further: "What are the factors 
which may make some pharmaceutical products more sensitive than others to the adverse 
effects of temperature spikes of up to 30 °C?" 
The form of the Arrhenius equation used by Grimm (6) in his calculation ofMKT 
assigns an Energy of Activation of 83kJ/mole. This value was obtained by Grimm from a 
survey which he made of literature reports the Energy of Activation for a variety of drugs 
as being a mode or average value. Obviously, products with energies of activation which 
are significantly different from the Grimm average will show differing susceptibilities to 
changes in temperature such as are qualified by MKT determinations. 
Where solvolysis is the route of degradation the Grimm value is probably more 
than reasonable and, of course, hydrolysis is a very common mode of degradation. 
However, for drug products for which oxidation is the primary route of degradation the 
energy of activation will be significantly less, values of the region of about 20 to 50 
kJ/mole are not unlikely. Drug products, which have, lower than average energies of 
activation will be less sensitive to temperature stress than the Grimm average. 
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( Conversely, there are drug products which degrade by mechanisms characterized by 
energies of activation substantially greater than 83kJ/mole. Such products will be more 
sensitive than the Grimm average to temperature stress. 
The normal conventional method of determining a shelf life (SL) for a 
pharmaceutical product is to determine the intersection of the 95% confidence bound for 
the isothermal (storage temperature) regression line with the 90% potency value. The 
time given by such an exercise is the maximum, which can be assigned as the shelf life. In 
practice this period determined (termed by A.J. Smith) as the conformance period (CP) is 
often substantially greater than the shelf life. Thus suppose we determined that 
conformance periods were 1.1 , 12.2, and 38.0 months, for three different products, it is 
likely that the respective shelf lives would be 1, 12 and 36 months. The difference 
between the conformance period and the assigned shelf life, in effect, provides an 
additional safety margin with respect to stability. Of course, since conformance periods 
are not normally publicly available it is not east to quantify the extent ofthis extra margin 
of safety for any given product. 
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METHODS 
The data used in this paper were computer generated. In the studies of the effect 
of temperature spikes on MKT and hence shelf life we used idealized square wave spikes 
such that temperature is deemed to rise instantaneously (Fig. I). (Some limitations of this 
model are considered in a later part ofthis paper). For example, for a one month spike we 
select a virtual product stored isothermally at exactly 25 °c and cause the temperature to 
instantaneously increase to 30 °c. At the end of one month the temperature is required to 
revert instantaneously to the former value of 25 °c. Knowledge of the time for which the 
product was subjected to 30 °c allows us to calculate the MKT for products with 
different energies of activation, shelf lives or conformance periods. With the new 
calculated MKT we are able to determine whether or not the new MKT has adversely 
affected the shelf life of the product, assuming a first order degradation process. 
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RESULTS AND DISCUSSIONS 
Table I shows the effect of a one month 30 °c spike on MKT values of systems 
all of which have a baseline storage temperature of25 °c and an activation energy of 83 
kJ/mole. As can be seen if the conformance period is slightly greater than the assigned 
shelf life the spike stress is not sufficient to invalidate the shelf life. However, when the 
shelf life is exactly equal to the conformance period the MKT (calculated to include the 
effect of the spike) is in excess of 25 °c and thus assigned shelf life is now invalid. 
Table II shows the effect of varying energy of activation on spike effects for two 
sets of system, one with SL of 1 month and the second with SL values of 12 months. It 
can be seen that the spike effects on MKT are indeed somewhat dependent on the value 
of activation energy. Thus, for systems with a SL of 12 months the effect of the spike on 
the MKT is 0.45 °c for products with an energy of activation of 55kJ/mole. This effect is 
not large and thus suggests that in most cases the use of the Grimm average for the 
energy of activation is unlikely to lead to major error. 
Table ill shows the effect of increasing spike stress from 0.01 months (i.e. about 7 
hours) at 30 °c to 2 months at 30 °c. As can be seen for the smallest spike the effect on 
MKT values is almost negligible even for products which only have a shelf life of 1 
month. As the length of the spike is increased the effect on MKT values, especially for 
the systems with short shelf lives, becomes, increasingly significant. 
The data presented in Tables I, II and ill is all derived for systems with a baseline 
storage temperature of25 °c. This is, of course, a worst case scenario. Table IV shows 
results for various spike stress, and shelf lives when the baseline temperature is 22.5 °c 
(i.e. in the middle of the 20-25 °c range). As can be seen, with the exception of two one 
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month shelf life systems, the MKT values all remain under 25 °c even with a 2 month 
30°C spike. 
Table V shows comparable data for a best case scenario for systems with a 
baseline storage temperature of 20 °c. As would be expected such systems are especially 
resistant to the adverse effect of spike stress although even in this case some of the one-
month shelf life products are adversely affected by the longer spikes. 
In all the calculations presented in this paper we have assumed that the 
degradation process was governed by first order kinetics. Calculations have shown that 
using zero order degradation kinetics does not affect the conclusions reported in this 
paper. 
Obviously, the square wave model used for the calculations reported in this paper 
is not likely to exist in actuality. However, it is suggested that, although the model has 
limitations, conclusions drawn from the use of this model are highly likely to be 
applicable to real storage conditions. In Fig.1 we show a square wave and a non-square 
wave spike which have the same amount of energy input (i.e. area under the temperature 
time curve from the baseline). Because of the logarithmic nature of the Arrhenius 
relationship the MKT of the square wave is slightly higher than that of the spike for the 
period Ts. However, the effect is small and thus it is legitimate to use the square wave 
model for studies of this type. Certainly, for investigations designed to elucidate the 
relative effects of such values as conformance periods, shelf lives or energies of 
activation as described in this paper this model is valid. 
It is recognized that temperatures recorded in a storage area, at some detector 
location, will not always necessarily reflect the actual temperature of pharmaceutical 
52 
products stored in the area. Depending on the nature of the heating/air conditioning 
system and airflow efficiency in the area there may be cold spots or hot spots. Certainly, 
if a storage area is overcrowded with packages airflow will probably be seriously 
impaired. Thus, it is important that all warehouses or other storage areas used for 
pharmaceutical products should not be overloaded and should allow a free flow of air in 
all parts of the unit. The thermodetector used as the temperature probe for a warehouse or 
other unit should be placed at a location which may reasonably be regarded as 
representative of the average temperature. When there is any doubt on this point a 
conservative approach should be used. Thus, place the detector higher in the room rather 
than closer to the floor. 
When continuous monitoring of temperature is obtained, as for example, with 
chart recorders there may be some quite transient spikes-caused perhaps by leaving a 
door open - which may have very little effect on the temperature of drug products stored 
in the area. All products have a finite thermal capacity and thus, for example, a liter glass 
bottle of aqueous injection has a specific heat of about 5 kJ per 0c. A current of warm air 
at 30 °c flowing over this bottle, even if it does not have an overwrap or other pack, 
would have little effect on the temperature of the product if the exposure to the warm air 
was for a short period. 
A question that naturally comes to mind when we consider the effect of 
temperature spikes on drug product stability is: Don 30 °c, 1 hour spikes have the same 
adverse effect on drug product stability as one 30 °c, n hour spike? Using the model 
developed in this paper the answer is: Probably yes, at least in a semi-quantitative way 
for chemical degradation. However, for some physical changes e.g. loosening of a plastic 
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( cap the answer to the question No. Cap loosening and some other adverse physical 
changes are more affected by temperature change per se rather than MKT. 
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CONCLUSION 
The effect of temperature spikes on MKT has been evaluated. It appears that for 
systems with a baseline storage temperature of 22.5 °c total spikes equivalent to 2 
months at 30 °c may be tolerated ifhe shelf life is 12 months or more. If the baseline 
storage temperature is more than 22.5 °c or the shelf life is less than 12 months then 
adverse affects on the validity of the assigned shelf life are more likely. It is highly 
improbable that a single 30 °c spike of seven hours or less would adversely affect the 
shelf life of any otherwise normal product. 
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( Table I: Effect of a 1 month 30 °c spike on the Shelf life of drug products all of 
which have an activation energy of 83 kJ/mole. 
Conformance Shelf life MKT including New CP Is Shelf life still 
Period (CP) (SL) spike (°C) (months) acceptable? 
J_month~ {months)_ 
1.000 1.000 30.000 0.575 x 
12.00 12.00 25.532 11.31 x 
24.00 24.00 25.270 23.37 x 
28.00 24.00 25.232 27.29 ., 
36.00 36.00 25.181 35.28 x 
39.00 36.00 25.167 38.21 ..,, 
41.00 36.00 25.159 40.28 ., 
62.00 60.00 25.105 61.28 ., 
65.00 60.00 25.100 64.28 ., 
X - SL is not valid after spike 
~ - SL is still acceptable 
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( Table II: Effect of activation energy on the Shelf life of products subjected to a one 
month 30 °c spike. 
Activation energy 
',1H J/mole 
MKT including 
spike (°C) 
New CP 
(months) 
System with 1.0 month SL and CP <![_I. 1 month. 
55 29.608 0.785 
70 29.625 0.715 
95 29.650 0.611 
110 29.665 0.555 
120 29.674 0.521 
~tem with 12. 0 months SL and CP o_[) 3. 0 months. 
55 25.450 12.57 
70 25.472 12.43 
95 25.511 12.17 
110 25.537 12.00 
120 25.554 11.88 
X - SL is not valid after spike 
" - SL is still acceptable 
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Is Shelf life (SL) 
still acceptable? 
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Table III: Effect of spike duration on Shelf life for products with an activation 
energy of 83 kJ/mole with a baseline at 25 °c 
Conformance Shelf life (SL) MKT including New CP Is Shelf life 
Period (CP) (months) spike (°C) (months) still 
{month& accep!able? 
Spjke..J!!.r 0.01 month at 30 0 c 
1 1 25.065 0.993 x 
12 12 25.005 11.99 x 
24 24 25.003 23.99 x 
36 36 25.002 35.99 x 
0 Spjkef!!r 0.1 month at 30 C 
1 1 25.635 0.931 x 
12 12 25.055 11.93 x 
24 24 25.027 23.93 x 
36 36 25.018 35.93 x 
0 Spjkef!!r 0.5 month at 30 C 
1 1 27.820 0.731 x 
12 12 25.270 11.64 x 
24 24 25.136 23.64 x 
36 36 25.091 35.64 x 
0 Spjkef!!r 1 month at 30 C 
1 1 30.000 0.576 x 
12 12 25.532 11.31 x 
24 24 25.270 23.29 x 
36 36 25 .181 35.28 x 
0 Spjke..J!!.r 2 months at 30 C 
12 12 26.035 10.69 x 
24 24 25.532 22.61 x 
36 36 25.358 34.59 x 
X - SL is not valid after spike 
~ - SL is still acceptable 
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( Table IV: Effect of spike duration on Shelf life for products with an activation 
energy of 83 kJ/mole with a baseline at 22.5 °c 
Conformance Shelf life (SL) MKT including New CP Is Shelf life still 
Period (CP) (months) spike (°C) (months) acceptable? 
l_monthsj_ 
Spjkef!!r 0.01 month at 30 0 c 
1 1 22.614 1.310 >I 
12 12 22.51 0 15.91 >I 
24 24 22.505 31.84 >I 
36 36 22.503 47.77 >I 
0 Spjkef!!r 0.1 month at 30 C 
1 1 23.578 1.174 
" 
12 12 22.595 15.76 >I 
24 24 22.548 31.68 >I 
36 36 22 .532 47.61 >I 
0 Spjkef!!r 0.5 month at 30 C 
1 1 26.966 0.803 x 
12 12 22.965 15.11 >I 
24 24 22.735 31.01 >I 
36 36 22.657 46.94 >I 
0 Spjkef!!r 1 month at 30 C 
1 1 30.000 0.576 x 
12 12 23.407 14.37 
" 
24 24 22.965 30.21 >I 
36 36 22.812 46.11 >I 
0 Spjkef!!r 2 months at 30 C 
12 12 24.234 13.08 
" 24 24 23.407 28.73 
" 36 36 23.114 44.56 >I 
X - SL is not valid after spike 
~ - SL is still acceptable 
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( Table V: Effect of spike duration on Shelf life for products with an activation energy of 83 kJ/mole with a baseline at 20 °c 
Conformance Shelf life (SL) MKT including New CP Is Shelf life still 
Period (CP) (months) spike (°C) (months) acceptable? 
J_monthsl 
S_pj.kefEr 0.01 month at 30 0 c 
1 1 20.177 1.734 .., 
12 12 20.015 21.21 .., 
24 24 20.007 42.45 .., 
36 36 20.005 63 .69 .., 
S_pj.kefEr 0.1 month at 30 0 c 
1 1 21.632 1.466 .., 
12 12 20.148 20.88 .., 
24 24 20.074 42.12 .., 
36 36 20.050 63.36 .., 
S_pj.kefEr 0.5 month at 30 0 c 
1 1 26.258 0.869 x 
12 12 20.716 19.55 .., 
24 24 20.365 40.73 .., 
36 36 20.245 61.94 .., 
0 S_pj.kefEr 1 month at 30 C 
1 1 30.000 0.576 x 
12 12 21.379 18.11 .., 
24 24 20.716 39.10 .., 
36 36 20.483 60.26 .., 
0 S_pj.kefEr 2 months at 30 C 
12 12 22.579 15.79 .., 
24 24 21.380 36.22 .., 
36 36 20.942 57.15 .., 
X - SL is not valid after spike. 
~ - SL is still acceptable. 
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Fig 1. Variation of temperature with time for a spike. 
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( 
Some Studies of the Stability of Compounded Cefazolin Ophthalmic Solution 
~!f Accepted for publication in International Journal of Pharmaceutical Compounding 
Abstract 
The chemical stability of three compounded batches of Cefazolin Ophthalmic 
Solution was monitored by a stability-indicating HPLC assay. The degradation was 
governed by first-order kinetics, and the effect of temperature on reaction rate was in 
accordance with the Arrhenius equation at and above 17 °c. Although the stability of all 
the three batches was essentially the same, buffering the formulations may be useful. 
Even using a most cautious and conservative approach to the assignment of Beyond-use 
date for this type of product, it appears that if the product is stored at Controlled Room 
Temperature a Beyond-use date of six days would be fully justifiable. If the product is 
stored in a refrigerator, then a Beyond-use date of fourteen days could be assigned. 
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I. INTRODUCTION 
The recent resurgence in compounding activities by a substantial number of US 
pharmacists ( 1) and the passage by the Congress of the 1997 Food and Drug 
Administration Modernization Act have been factors , that have increased the attention 
being given to the stability of pharmacist compounded (as distinct from manufactured) 
pharmaceutical products. Concurrent with these developments is an increased concern 
about the suitability of storage and packaging during distribution. Thus, the use of the 
concept of Mean Kinetic Temperature as a means to monitor pharmaceutical warehouses 
has gained the attention of regulators in both the European Union and the United States 
(2,3). Many pharmaceutical scientists recognize that success in assuring the quality of 
many pharmaceutical products at the time of preparation means that it is now appropriate 
to devote more attention to the quality of products during storage and distribution (4). 
Cefazolin sodium is a broad-spectrum ~-lactam anti-bacterial drug closely related to 
penicillin (5). Cefazolin sodium is often administered topically to the eye to treat ocular 
and peri-ocular infections (6,7). Although the ointment form of cefazolin sodium would 
provide longer contact with ocular tissues, the solution form can be more conveniently 
used. However, a potential problem of stability of cefazolin sodium in aqueous solution 
exists. Cefazolin stability is influenced primarily by pH and temperature (8). Formulation 
is accomplished by reconstituting Cefazolin sodium in 0.9% sodium chloride solution (9) 
without pH adjustment or buffering. 
In the present paper we report preliminary studies of the chemical stability of 
Cefazolin Sodium Ophthalmic Solution. Three batches were prepared and samples were 
stored isothermally at 7 °, 17 °, 25 ° and 40 °. A specific HPLC stability-indicating assay 
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( was used to determine the potency of the samples, and the raw experimental data were 
transformed using conventional kinetic and statistical methods so that estimates of 
Beyond-use-date could be made. 
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II. EXPERIMENTAL 
Chemicals: USP Cefazolin RS Lot J; cefazolin sodium, Ancef®, SmithKline Beecham; 
0.9% sodium chloride injection, USP, Abbott Laboratories; thimerosal [Mercury,ethyl(2-
mercaptobenzoato-S)-,sodium salt] , USP/NF, Gallipot; sodium phosphate dibasic 
anhydrous, Ultrapure Bioreagent grade, J.T.Baker; citric acid monohydrate, ACS reagent 
grade, J.T.Baker; potassium phosphate monobasic, Sorensen grade, Fisher Scientific; 
acetonitrile, high purity solvent, Burdick and Jackson; Milli-Q® water, Millipore. 
Equipment: Spectra Physics Model 8800 ternary pump using a gradient mobile phase 
pumping program; Waters Model 991 photodiode array HPLC detector; Waters 
Millenium Software version 2.1 O; Waters Model 717 Plus autosampler with temperature 
of 4 °c and 10-µl injection; Waters µBondapak C18 column, 10-µm, 30-cm X 3.9-mm; 
Scientific Resources Inc. Model 83099Rc column temperature controller set at a 
temperature of 25 °c; Millipore HVLP 0.45-µm filters used for buffer preparation; Sterile 
Dropper bottles. 
Formulation Preparation: The preparation of the ophthalmic solution followed the 
procedure in the preview of a new pharmacy compounding monograph of Cefazolin 
Ophthalmic Solution (9). The preparation steps are as follows : 
Diluent: A 2-mg portion ofThimerosal was added to a 100-mL bottle of 0.9% sodium 
chloride injection and mixed well. 
Cefazolin Ophthalmic Solution (COS): The COS formulation specifies that 10 mL of a 
50mg/mL solution of cefazolin sodium in Diluent be made. Dissolve 500mg of Cefazolin 
sodium (Ancef®) in 10 mL of Diluent. A 7.0-mL aliquot of this solution is then diluted 
to 100 mL (3.5mg/mL) with Diluent. The solution is then transferred to the sterile 
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( ophthalmic dropper bottles (3 mL) and stored at four different temperatures (7°, 17°, 25° 
and 40 °). 
Solutions for Gradient HPLC assay procedure: 
pH 3.6 Buffer: A 0.9 g portion of anhydrous sodium phosphate di basic and 1.298 g of 
citric acid monohydrate were dissolved and diluted to 1000 mL with water. This solution 
was filtered through a Millipore HVLP 0.45-µm membrane filter. 
pH 7.0 Buffer: A 5.68 g portion of anhydrous sodium phosphate dibasic and 3.63 g 
portion of potassium phosphate mono basic were dissolved and diluted to 1000 mL with 
water. This solution was filtered through a Millipore HVLP 0.45-µm membrane filter. 
Standard preparation: A 35-mg portion, accurately weighed, of USP Cefazolin 
Reference Standard was transferred to a 10.0-mL low actinic volumetric flask and 
dissolved and then diluted to volume with pH 7 .0 Buffer. A 1.0-mL portion ofthis 
solution was transferred to a 10.0-mL low-actinic volumetric flask and diluted to volume 
with pH 7.0 Buffer. 
Assay preparation: A l.OmL aliquot of the COS preparation was transferred to a 10.0mL 
low-actinic volumetric flask and diluted to volume with pH 7.0 Buffer for all the 3 
batches. All injections were performed in triplicate. 
Pump gradient program: The flow rate was maintained at 2.0 mL per minute throughout 
the run. The column was equilibrated with pH 3.6 Buffer. After the injection, the gradient 
change to acetonitrile is completed in 15 minutes. The column is then equilibrated back 
to pH 3.6 Buffer for 10 minutes before the next injection. 
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Pump Gradient Program Table: 
Time (min) 
0.0 
15.0 
15.l 
25.0 
pH 3.6 Buffer (o/ov/v) 
90 
20 
90 
90 
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Acetonitrile(o/ov /v) 
10 
80 
10 
10 
ID. RESULTS AND DISCUSSION 
Fig. I shows some typical plots of percentage drug remaining as a function of 
time. The results for all three batches at all four temperatures appeared similar. The 
correlation coefficients for the three batches A, Band C were 0.84, 0.84, & 0.70 at 7 °, 
0.94, 0.96, & 0.81 at 17 °, 0.99, 0.99, & 0.96 at 25 °, and 0.99, 0.99 & 0.99 at 40 °, the 
degrees of freedom being six. The high correlation of percentage remaining and time at 
17 °, 25 °, and 40 ° provided strong evidence that the degradation was governed by first-
order kinetics. (The relatively low r values at 7 ° and 17 ° reflected the low extent of 
reaction during the brief study period: the percentage of drug remaining was almost 
independent of time. The correlation coefficient approaches zero, as the y value becomes 
less dependent on the x value, in this case time. The analysis was further confounded by 
the possibility of a competing reaction (vide infra).) 
Table I records the calculated first-order rate constants for the three batches. The 
scatter in the apparent rates may reflect the unbuffered nature of the formulation. The 
drug substance is a ~-lactam, which should be susceptible to alkaline hydrolysis . 
Cefazolin sodium is also an aliphatic car boxy late salt, a simple solution of which would 
be poorly poised with respect to pH. The alkaline nature of this salt would make the 
product solution susceptible to partial neutralization due to absorption of atmospheric 
carbondioxide and thus to significant interbatch variation in pH. Such variation in 
hydroxyl-ion activity would alter the hydrolytic degradation rate. This suggests the 
desirability of buffering this type of formulation. Fig. 2 depicts the corresponding 
Arrhenius plots. While the correlation coefficients for these plots were close to unity, the 
residuals clearly showed that the linear model failed at 7 °. This suggests that a different 
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decomposition mechanism predominated at the lowest temperature. (10) Without the 7 ° 
data, the correlation coefficients for the three batches A, B, and C were 0.99, 0.99, and 
0.99 (two degrees of freedom), which provided strong evidence that the effect of 
temperature on the degradation was in accordance with the Arrhenius equation. Table II 
lists the values of Arrhenius parameters for the three batches. Although the activation 
energies (Ea) were not detected as being statistically different at the 95% confidence 
level, further work would be necessary to demonstrate this conclusively. Using the data 
obtained at 7 ° and 25 ° estimates have been made from the lower 90%confidence bounds 
of the conformance periods for all three batches (Irrespective of mechanism the 7 ° data 
are reliable). Table Ill presents the results of this statistical evaluation, and Fig. 3(a) & 
Fig. 3(b) show the example of the type of plot that was obtained. (The conformance 
period is defined as the time at which the 90% lower confidence bound intersects with 
potency value of 90% of label claim). 
Since at 7 °, the degradation proceeded so slowly that the loss of potency never 
reached 10%, we cannot estimate the precise value of the conformance period. For all 
three batches it is clearly significantly in excess of fifteen days, which might therefore be 
a reasonable Beyond-use-date for products stored in a refrigerator. At 25 ° a Beyond-use-
date of six days might well be regarded as acceptable. 
IV. CONCLUSION 
The data reported in this paper are limited, pertaining only to three batches made 
at the same site. Nevertheless, it does appear that if this product were stored in a 
refrigerator, a Beyond-use-date of two weeks would be judiciously conservative. 
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Tablel: Degradation rate constants (hr-1 *103) 
Batch 7 UC, -- 1 7 c 25 c 40 c 
A 0.115 0.207 0.461 3.224 
B 0.138 0.207 0.461 3.224 
c 0.092 0.138 0.690 3.450 
..... 
Table II: Values of Arrhenius parameters 
A B c 
Activation energy 
-..l (kJ/mole) 91.5 91.5 103 
Vl 
Frequency factor 
(/hrs) 5.28E+12 5.28E+12 6.28E+14 
-.} 
0\ 
Table III: Conformance periods in days 
Temperature Batch A 
7 °c 15+ 
25 °C 7.7 
....... 
Batch B Batch C 
15+ 15+ 
7.3 7.7 
.....) 
.....) 
Figure 1: Plot of the log 0/o drug remaining as a function of time at 7, 
17, 25 & 40 deg C for batch A 
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Figure 2: Arrhenius parameters (from three 
temperature data points) 
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Figure 3(a): Prediction of Beyond-use date at 7 deg C for 
batch A 
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Potential of known individual single tablet assay by near-IR for the assignment of 
shelf-life 
*To be submitted for publication 
During the past decade or so the use of near-IR for pharmaceutical purposes has 
substantially increased (1). Since it is possible to use near-IR for non-destructive 
determination of the stability of known individual tablets, there is an exciting possibility 
of using the near-IR in stability studies which have a substantially improved precision 
compared to conventional methods. 
The normal method of assigning a shelf life often consists in essence of the 
following exercise. Data on percentage label claim, obtained by use of a stability 
indicating assay, is plotted as a function oftime and the regression line and its 90% 
confidence bounds determined by conventional statistical methods. The intersection of 
the lower 90% confidence bound and the 90% potency line is used to determine the 
conformance period (i.e. the time at which a 95% level of assurance the product is still of 
acceptable potency). Since conformance periods are often non-integral values we 
normally round down from a conformance period to obtain the shelf life which we assign 
to the product. Thus, if we obtain a conformance period of 28.7 months we would 
probably assign a two-year shelf life to the product. 
The wider the 90% confidence envelope round the mean regression line is the 
shorter the conformance period will be. Thus anything which can be done to improve the 
precision of the data from which the regression line is obtained has the potential of 
significantly improving the shelf life of pharmaceutical products, without any change to 
formulation or processing variables. 
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When there are significant differences between the near IR spectrum of a parent 
drug and its degradation products there is the possibility of developing a near IR stability 
indicating assay for tablets containing the drug. Since the near IR method can be used as 
a non-destructive method it is possible to use the same tablet repeatedly. Further if the 
individual tablet used can be identified the stability data has the potential to significantly 
lengthen a products shelf life. 
One possible way of implementing this new concept in stability testing would be 
as follows . Ten representative tablets are selected and individually packaged in the final 
market container and then stored in the retained stability sample chamber. At the 
appropriate time intervals the test tablets are removed from the stability chamber and 
non-destructively assayed for potency. They are then returned to the storage chamber. 
Thus, using this approach we will accumulate stability data on ten individual tablets. 
For stability data on tablets obtained by conventional methods the scatter of 
experimental points seen in plots of percentage label claim as a function of time is due to 
a number of factors including both the imprecision of the assay and allowable content 
uniformity variation. For any USP tablet monograph there is a relevant content 
uniformity specification. In many instances, the allowable content uniformity limits are 
characterized by a standard deviation of six percent. Thus, any stability method, which 
can remove variability caused by allowable content uniformity limits, will have an 
improved precision. 
Table I depict some virtual data for the stability of a tablet formulation derived by 
use of a near IR stability-indicating assay. It will be seen that the average potency value 
at time zero is very close to 100% and that the variability associated with the assay is 
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low. The raw experimental data as shown in Table I could all be used without regard for 
the identity of individual tablets and plotted in a conventional manner to obtain an 
estimate of the conformance period (Fig.l). However, since when using the near IR as a 
stability indicating assay, as described in this paper, we are able to follow the degradation 
of each of the ten individual tablets we can legitimately interpret our data in a way which 
allows us to circumvent content uniformity differences. 
For potency values at all time intervals we normalize data by multiplying each 
value by (XO/PO) where PO is the potency at time zero of the relevant potency at time t. 
the calculated values are shown in Table I in parenthesis. We then plot the values so 
obtained and determine the conformance period (Fig.2). 
Obviously, the ability to follow the degradation in individual tablets and hence 
negate the variance due to content uniformity significantly tightens the 90% confidence 
envelope and thus improves our conformance period. The extent of the improvement that 
will be obtained by us eof this approach depends on the precision of the assay and the 
content uniformity limits for any given product. This approach could be adapted for any 
other non-destructive assay method, which can be shown to be stability indicating. For 
drugs, such as L-thyroxene, for which stability is a considerable problem, this type of 
approach would be most valuable. 
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Figure 1. Conformance period of tablets determined using NIR with the original 
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APPENDIX A 
LIST OF PUBLICATIONS 
The following is a list of the journals the manuscripts were prepared for and their 
publication status. 
Manuscript I 
TRENDS IN STABILITY TESTING WITH EMPHASIS ON STABILITY DURING 
DISTRIBUTION AND STORAGE 
Published in Drug Development and Industrial Pharmacy, 25(7): 857-868 (1999) 
Manuscript II 
EFFECTS OF TEMPERATURE SPIKES ON MEAN KINETIC TEMPERATURE AND 
SHELF LIFE 
Submitted to Pharmacopeial Forum 
Manuscript ID 
SOME STUDIES OF THE STABILITY OF COMPOUNDED CEFAZOLIN 
OPHTHALMIC SOLUTION 
Accepted for publication in International Journal of Pharmaceutical Compounding 
Manuscript IV 
POTENTIAL OF KNOWN INDIVIDUAL SINGLE TABLET ASSAY BY NEAR-IR 
FOR THE ASSIGNMENT OF SHELF LIFE 
To be submitted for publication 
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APPENDIXB 
ROLE OF CO-AUTHORS IN PAPERS 
Dr. Christopher T.Rhodes, my major Professor, is instrumental in getting the thesis 
done in manuscript form. His enthusiasm, guidance and positive directions played a 
major role in all the four manuscripts, without which it would have not been possible to 
present the thesis in this format. 
Manuscript ID is co-authored by Dr. C.T.Rhodes, Dr. Richard F. Lindaeur and Dr. Lee 
T.Grady. 
Dr. Lee T.Grady is the Executive Vice-President, Drug Standards Development, USP. He 
was instrumental in getting the summer fellowship . His involvement in the project in his 
capacity made the work progress in a faster pace than expected. Also, his suggestions and 
recommendations were valuable. 
Dr. Richard F.Lindaeur is the Director ofDRTL-USP. He acted as an acting major 
Professor during my stay in USP. His in-depth involvement in the research part, guidance 
and monitoring of the work, in his capacity, created a wonderful atmosphere in the 
laboratory, which was critical in the completion ofthis project. His involvement in 
editing the manuscript was also of immense value. 
Manuscript IV is co-authored by Dr. C.T.Rhodes and Dr. Karen M.Morrisseau. 
Dr. Karen M.Morrisseau worked on the stability of tablets using NIR data for her Ph.D., 
which was submitted in 1996. This manuscript has the theme taken from her Dissertation 
and also some of her ideas were used. 
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APPENDIXC 
(Supplement to Manuscript III) 
The raw data was obtained from the analysis of drug content using USP stability-
indicating HPLC assay. The percentage of drug remaining as a function of time for 
batches A, B & Cat 7°, 17°, 25° & 40 °c were incorporated in Tables I, II, III & IV 
respectively. The log percentage of drug remaining as a function oftime at 7, 17, 25 & 
40 deg C for batch A was depicted in Fig 1 of Manuscript III. The log percentage of drug 
remaining as a function of time at 7, 1 7, 25 & 40 deg C for batches B & C are depicted 
in Figs 1 & 2. The slopes of the regression lines were used to calculate the values of k at 
different temperatures for all the three batches. Using the k values and their respective 
temperatures, the Arrhenius plots were constructed. The correlation coefficients are not 
close to unity at 3 degrees of freedom (four temperature data), which is depicted in Fig 7. 
Also, the calculated Ea values are deviating from Grimm average. This may be due a 
different mechanism occurring at 7 deg C. Therefore, Arrhenius parameters were 
calculated using 17, 25 and 40 deg C data in which the correlation coefficients are close 
to unity at 2 degrees of freedom (see manuscript III). 
The 90% confidence intervals for the percentage label claim were obtained using 
the software package MINITAB®. The Beyond-use dates at 7° and 25 °c for batches A, 
B & C were obtained using the 90% confidence bounds. The conformance periods (in 
days) were obtained when 90% label claim intersects the 90% lower confidence bound. 
The beyond-use date plots were depicted in Figs. 3, 4, 5 & 6 for batches B & Cat 7 ° & 
25 °c (see Figs. 3(a) & 3(b) in Manuscript Ill for batch A). 
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Table I. Percentage of drug remaining after predetermined intervals at 7 °c for batches A, B & C 
TimeJbrtl A B c 
0 100.0 100.0 100.0 
67 98.40 98.56 101.3 
113 100.2 100.6 102.1 
161 99.10 98.61 100.1 
237 97.30 98.10 99.94 
281 96.00 96.70 99.08 
311 96.92 94.72 97.83 
\0 
"""' 
Table II. Percentage of drug remaining after predetermined intervals at 17 °c for batches A, B & C 
Time_(hr& A B c 
0 100.0 100.0 100.0 
67 97.58 98.97 98.00 
113 98.86 99.34 100.9 
161 96.05 96.29 99.26 
237 93.61 95.82 97.20 
281 94.40 94.84 96.50 
311 93.65 93.72 95.50 
"' Vl 
Table m. Percentage of drug remaining after predetermined intervals at 25 °c for batches A, B & c 
Time _(_hrs}_ A B c 
0 100.0 100.0 100.0 
67 95 .51 95.34 102.5 
113 94.47 94.66 95.69 
161 91.79 92.96 94.00 
237 87.03 86.89 88.96 
281 86.27 85.17 85 .87 
311 84.77 83 .81 85.61 
\0 
°' 
Table IV. Percentage of drug remaining after predetermined intervals at 40 °c for batches A, B & C 
Time_(hr~ A B c 
0 100.0 100.0 100.0 
67 81.40 81.80 85.67 
113 72.18 71.15 73.80 
161 61.10 61.52 63 .34 
237 46.35 46.16 47.01 
281 40.10 39.71 39.87 
311 37.80 36.01 35.84 
Figure 1: Plot of the log 0/o drug remaining as a 
function of time at 7, 17, 25 & 40 deg C for batch B 
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Figure 2: Plot of the log 0/o drug remaining as a function 
of time at 7, 17, 25 & 40 deg C for batch C 
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Figure 3: Prediction of Beyond-use date at 7 deg C for 
batch B 
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Figure 4: Prediction of Beyond-use date at 7 deg C for 
batch C 
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Figure 5. Prediction of Beyond-use date at 25 deg C 
for batch B 
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Figure 6. Prediction of Beyond-use date at 25 deg C for 
batch C 
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Figure 7: Arrhenius parameters (from four 
temperature data points} 
<> y = -3899.1x + 9.8585 
R2 = 0.9588 
o y = -3711.4x + 9.2419 
R2 = 0.9366 
A y= -4421 .5x+11 .613 
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SUMMARY OF CONCLUSIONS 
1. The increasing attention is now being given to the possible effects of storage and 
transport on the stability of pharmaceutical products. This lead to an improved 
level of confidence about the stability of drug products among the patients. 
2. The effect of temperature spikes on mean kinetic temperature has been evaluated. 
3. For a system with a baseline storage temperature of 22.5 De total spikes 
equivalent to 2 months at 30 De may be tolerated if the shelf life is 12 months or 
more. 
4. If the baseline storage temperature is more than 22.5 De or the shelf life is less 
than 12 months then adverse effects on the validity on the assigned shelf life are 
more likely. 
5. A single 30 De spike of 7 hours or less would probably not adversely affect the 
shelf life of any normal product. 
6. Compounded cefazolin ophthalmic solution, when stored at refrigerator and CRT 
conditions, a beyond-use date of 2 weeks and six days respectively can be 
assigned. 
7. The activation energy of the product (Compounded cefazolin ophthalmic 
solution) was found to be almost in accordance with the Grimm's average value. 
8. The conformance period of tablets determined using NIR stability-indicating 
assay was found to be more in the normalized data than the original data. 
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